Loading
Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer.
Ignace Vergote was principal investigator of EORTC 55971, which showed neoadjuvant chemotherapy followed by interval surgery is non-inferior to primary surgery in advanced ovarian cancer with less morbidity, and of innovaTV 301, in which tisotumab vedotin improved survival in recurrent cervical cancer. He founded the ENGOT network of European gynaecological trial groups and has led more than 30 phase 3 trials.
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tissue factor, Tisotumab vedotin, Cervical cancer and the tags ovarian, cervical, cooperative-group.
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tisotumab vedotin.
Shares Tissue factor, Tisotumab vedotin, Cervical cancer.
Shares Cervical cancer and the tags cervical, cooperative-group.
Shares Ovarian cancer and the tags ovarian, cooperative-group.
Shares Antibody-drug conjugate (ADC), Ovarian cancer and the tags ovarian, adc.
Shares Cervical cancer, Ovarian cancer and the tag cooperative-group.
Shares Tisotumab vedotin, Cervical cancer, Antibody-drug conjugate (ADC).